|Bid||0.00 x 30000|
|Ask||0.00 x 30000|
|Day's Range||136.00 - 138.30|
|52 Week Range||116.00 - 142.96|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||28.62|
|Earnings Date||Jul 21, 2021|
|Forward Dividend & Yield||3.48 (2.53%)|
|Ex-Dividend Date||May 25, 2021|
|1y Target Est||N/A|
Dr. Shereef Elnahal, University Hospital CEO and former NJDOH Commissioner, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Is JNJ stock a buy after U.S. regulators recommended vaccinations resume with Johnson & Johnson's Covid vaccine following worries of blood clots? Shares are forming a flat base.
Two U.S. House panels have expanded their probe into problems at Emergent BioSolutions Inc's Baltimore plant and have asked Johnson & Johnson and AstraZeneca for documents related to their selection of the contract manufacturer for their COVID-19 vaccines. Manufacturing of J&J's vaccine at Emergent's plant in Baltimore was halted by the U.S. Food and Drug Administration following an error in which ingredients from AstraZeneca's shot, also being produced at the plant at that time, contaminated a batch of the J&J vaccine.